Sciety flags revived US biotech IPO market as 20 listings raise USD 6.1 billion in 2026
Bitget2026/09/28 09:14- Sciety flagged a rebound in US biotech investor appetite, marked by stronger IPO issuance and broad sector gains.
- 20 US drug-development biotech IPOs priced through mid-August 2026, raising about USD 6.1 billion.
- Six Nasdaq biopharma IPOs over the summer upsized, raising USD 1.6 billion.
- Parabilis Medicines raised USD 670 million, described as the largest biotech IPO on record.
- XBI was up more than 80% year-on-year by late August, pointing to improved sentiment.
- Most 2026 IPO issuers were late-stage, with 15 companies at or near Phase 2 or later.
- Europe and the Nordics could see a pickup in biotech demand in H1 2027 if the prior cycle’s lag repeats.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
